rifalazil
Rifalazil is an antibiotic substance that kills bacterial cells by blocking off the β-subunit in RNA polymerase. Rifalazil is used as a treatment for many different diseases. The most common are Chlamydia infection, Clostridioides difficile associated diarrhea (CDAD), and tuberculosis (TB). Using rifalazil and the effects that coincide with taking rifalazil for treating a bacterial disease vary from person to person, as does any drug put into the human body. Food interactions and genetic variation are a few causes for the variation in side effects from the use of rifalazil. Its development was terminated in 2013 due to severe side effects. — Wikipedia
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Nov 1, 2005 (NCT00251849)
Timeline
Indications
Mechanism of action
- DNA-directed RNA polymeraseINHIBITOR
DNA-directed RNA polymerase inhibitor
- DNA-directed RNA polymeraseINHIBITOR
DNA-directed RNA polymerase inhibitor
Chemistry & pharmacology
SMILES
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(=O)c(c5oc6cc(N7CCN(CC(C)C)CC7)cc(O)c6nc-5c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C- Mol. weight
- 941.09 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRifalazil ↗
- ChEMBLCHEMBL236297 ↗
Also known as
- 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin
- 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin
- 3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin
- abi1648
- abi 1648
- abi-1648
- benzoxazinorifamycin
- krm 1648
- krm-1648
- krm-1648
- krm-1648
- rifalazil
- rifalazil
- rifalazil
- rifalazil
- rifalazil
- rifamycin viii, 1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-(4-(2-methylpropyl)-1-piperazinyl)-1-oxo-
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01631201 | Phase 2 | Jul 1, 2012 | ActivBiotics Pharma |
| NCT00385385 | Phase 2 | Oct 1, 2006 | ActivBiotics Pharma |
| NCT00251849 | Phase 3 | Nov 1, 2005 | ActivBiotics Pharma |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ActivBiotics Pharma | For profit | 3 | 3 | 2 | 2005 |